Insilico's UAE Team Selects First AI-Designed Preclinical Candidate for Regional Drug Development

Stock News08:14

Insilico has officially nominated ISM0387, a novel MTA-cooperative PRMT5 inhibitor, as a preclinical candidate drug. This molecule was discovered locally by the company's UAE team using its proprietary Pharma.AI platform. The entire early-stage drug discovery process, from molecular design to optimization, was completed within the UAE in less than 12 months. During this period, hit compound series were generated within 30 days, and lead optimization was accomplished in six months. ISM0387 is an AI-designed inhibitor with a novel structure that demonstrated strong in vitro activity, selectivity, optimized brain-penetrating properties, and potent efficacy in disease models during preclinical studies, with clear dose-dependent trends. Due to its unique molecular structure and enhanced central nervous system penetration, ISM0387 offers a promising potential new treatment option for patients with glioblastoma. This nomination also marks Insilico's 30th AI-driven preclinical candidate to date. The announcement was made with the support and presence of the UAE's Emirates Drug Establishment, Abu Dhabi Department of Health, and Abu Dhabi Investment Office.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198852916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198852916","market":"hk","top_or_hot":-1,"title":"Insilico's UAE Team Selects First AI-Designed Preclinical Candidate for Regional Drug Development","media":"Stock News","content":"<p>Insilico has officially nominated ISM0387, a novel MTA-cooperative PRMT5 inhibitor, as a preclinical candidate drug. This molecule was discovered locally by the company's UAE team using its proprietary Pharma.AI platform. The entire early-stage drug discovery process, from molecular design to optimization, was completed within the UAE in less than 12 months. During this period, hit compound series were generated within 30 days, and lead optimization was accomplished in six months. ISM0387 is an AI-designed inhibitor with a novel structure that demonstrated strong in vitro activity, selectivity, optimized brain-penetrating properties, and potent efficacy in disease models during preclinical studies, with clear dose-dependent trends. Due to its unique molecular structure and enhanced central nervous system penetration, ISM0387 offers a promising potential new treatment option for patients with glioblastoma. This nomination also marks Insilico's 30th AI-driven preclinical candidate to date. The announcement was made with the support and presence of the UAE's Emirates Drug Establishment, Abu Dhabi Department of Health, and Abu Dhabi Investment Office.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico's UAE Team Selects First AI-Designed Preclinical Candidate for Regional Drug Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico's UAE Team Selects First AI-Designed Preclinical Candidate for Regional Drug Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-24 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico has officially nominated ISM0387, a novel MTA-cooperative PRMT5 inhibitor, as a preclinical candidate drug. This molecule was discovered locally by the company's UAE team using its proprietary Pharma.AI platform. The entire early-stage drug discovery process, from molecular design to optimization, was completed within the UAE in less than 12 months. During this period, hit compound series were generated within 30 days, and lead optimization was accomplished in six months. ISM0387 is an AI-designed inhibitor with a novel structure that demonstrated strong in vitro activity, selectivity, optimized brain-penetrating properties, and potent efficacy in disease models during preclinical studies, with clear dose-dependent trends. Due to its unique molecular structure and enhanced central nervous system penetration, ISM0387 offers a promising potential new treatment option for patients with glioblastoma. This nomination also marks Insilico's 30th AI-driven preclinical candidate to date. The announcement was made with the support and presence of the UAE's Emirates Drug Establishment, Abu Dhabi Department of Health, and Abu Dhabi Investment Office.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHAT","symbol_name":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","start_time":0,"source_url":"","article_id":"1198852916","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198852916","pubTimestamp":1776989694,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Insilico has officially nominated ISM0387, a novel MTA-cooperative PRMT5 inhibitor, as a preclinical candidate drug. This molecule was discovered locally by the company's UAE team using its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK1141":"生命科学工具和服务","AGIX":"通用人工智能 ETF-AGIX","AIPO":"Defiance AI and Power Infrastructure ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","03696":"英矽智能"},"translate_title":"Insilico阿联酋团队选择首个人工智能设计的临床前候选药物用于区域药物开发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":1,"03696":1,"AGIX":1,"AIPO":1,"CHAT":1},"content_text":"Insilico has officially nominated ISM0387, a novel MTA-cooperative PRMT5 inhibitor, as a preclinical candidate drug. This molecule was discovered locally by the company's UAE team using its proprietary Pharma.AI platform. The entire early-stage drug discovery process, from molecular design to optimization, was completed within the UAE in less than 12 months. During this period, hit compound series were generated within 30 days, and lead optimization was accomplished in six months. ISM0387 is an AI-designed inhibitor with a novel structure that demonstrated strong in vitro activity, selectivity, optimized brain-penetrating properties, and potent efficacy in disease models during preclinical studies, with clear dose-dependent trends. Due to its unique molecular structure and enhanced central nervous system penetration, ISM0387 offers a promising potential new treatment option for patients with glioblastoma. This nomination also marks Insilico's 30th AI-driven preclinical candidate to date. The announcement was made with the support and presence of the UAE's Emirates Drug Establishment, Abu Dhabi Department of Health, and Abu Dhabi Investment Office.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198852916","isCrawlerRequest":true}